FIELD: medicine.
SUBSTANCE: group of inventions relates to methods for detection of cancer sensitive to a compound of ATR inhibitor in a combination with DNA-damaging agent and to the treatment of subjects with such detected cancer, using ATR inhibitor in a combination with DNA-damaging agent. A level of CDKN1A activity in malignant tumor of a patient is measured. Measured activity of CDKN1A is compared with CDKN1A activity in reference tissue or cell. A patient is selected, having malignant tumor identified as tumor having reduced CDKN1A activity, for the treatment, using ATR IIA-7 or I-G-32 inhibitor in a combination with DNA-damaging agent, which is cisplatin or gemcitabine.
EFFECT: inventions allow for stratification of patients with malignant tumor for therapy, using ATR inhibitor in a combination with DNA-damaging agent with a synergetic response.
36 cl, 14 dwg, 5 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | 2016 |
|
RU2768621C1 |
| METHOD OF TREATING CANCER USING A COMBINATION OF CHK1 AND ATR INHIBITORS | 2015 |
|
RU2736219C2 |
| COMPOUNDS USED AS ATR KINASE INHIBITORS | 2013 |
|
RU2689996C2 |
| PHARMACEUTICAL COMPOUNDS | 2015 |
|
RU2687060C2 |
| CALICHEAMICIN DERIVATIVES AND THEIR ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2732568C1 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR USE THEREOF | 2013 |
|
RU2704445C2 |
| EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| COMBINATION OF MCL-1 INHIBITOR AND MIDOSTAURIN, ITS APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS | 2019 |
|
RU2818453C2 |
